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sidered in the statistical analysis (510 from the acampro-
sate cohort, 256 from the control group). The two
groups of the study population were comparable in terms
of sociodemographic variables. The number of abstinent
patients treated with acamprosate was 41.2% (per proto-
col analysis), only 25.4% (per protocol analysis) of all
patients in the control group were abstinent during the
study period. Although the drug costs are three times
higher in the acamprosate cohort the cost analysis re-
sulted in total costs of DM 3,026 ($1593) per patient/
year for the acamprosate group compared to DM 4,199
($2210) per patient/year in the control group, a signifi-
cant cost saving potential of DM 1,173 ($617). Hospital-
ization could be identified as the most cost-driving factor,
and was significantly higher in the control group. CON-
CLUSION: Based on the results of this study, it is sug-
gested that an initial expensive adjuvant treatment of al-
coholism leads to less cost than any other single therapy.
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OBJECTIVES: To quantify the cost-effectiveness of indi-
navir with zidovudine (ZDV) and lamivudine (3TC) com-
pared to ZDV3TC in patients with high and low base-
line viral load as cost per life-year gained (LYG) from a
third party payer perspective. METHODS: Progression
of HIV through 3 stages (CD4 200–500, CD4 200
No AIDS, AIDS) until death was modeled using a
Markov cycle tree, based on CD4 and viral load fac-
tors. Patients who failed to respond or progressed began
salvage therapy. Mortality, tolerability and disease pro-
gression rates were obtained from published sources. Six-
teen week clinical outcomes according to baseline viral
load (100,000 c/ml; 100,000 c/ml) were determined
from a randomized controlled trial (AVANTI II). Drugs
and medical care costs disaggregated by CD4 strata were
obtained from a Canadian HIV costing study. Future
costs and outcomes were discounted at 5%. RESULTS:
The incremental cost (1997 CDN $) per LYG with IDV/
ZDV/3TC vs. ZDV/3TC in patients with baseline viral
load below 100,000 c/ml was $68,353 per LYG. Indi-
navir/ZDV/3TC is more cost-effective in patients with
high baseline viral load (100,000 c/ml) at $24,852 per
LYG. The model was robust to probabilities and costs
tested in the sensitivity analysis. CONCLUSIONS: These
figures indicate that HAART therapies, such as indinavir/
ZDV/3TC provide important improvements at a reason-
able cost and thus are attractive both clinically and eco-
nomically, especially in patients with high baseline viral
load. Factors such as resistance and adherence to therapy
need to be considered in future models.
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Models of the clinical and economic impact of hyperten-
sion and the benefits of blood pressure (BP) control typi-
cally focus on either diastolic or systolic blood pressure
(DBP or SBP) but not both. For example, our previously-
reported Hypertension Burden of Illness Model consid-
ered only DBP and therefore could not address the issue
of systolic hypertension. OBJECTIVE: To estimate the
clinical and economic benefits of achieving both DBP and
SBP goals in treated hypertensives. METHODS: We re-
vised and updated our existing model which was de-
signed to forecast cardiovascular disease (CVD) incidence
and direct medical-care costs for specified populations,
such as the membership of a managed-care plan, and
simulates the effect of programs to improve BP control.
The underlying Framingham Heart Study (FHS) risk
equations, which previously quantified the relationship
between DBP and CVD risk, were replaced with new
FHS equations that incorporated both DBP and SBP. The
economic costs of CVD were estimated as in the earlier
version using major national health surveys and health-
care cost databases. RESULTS: We estimate that 9.6 mil-
lion persons aged 40–79 years in the US are treated for
hypertension but continue to have uncontrolled DBP
(90 mmHg) or SBP (140 mmHg). If all of these pa-
tients were treated to high-normal BP (140/90), an esti-
mated 414,000 CVD events would be prevented over 10
years resulting in medical care cost savings of $6.5 bil-
lion, an average of 43 events and $674,000 per 1000 pa-
tients. If such treatment were limited to patients with a
history of CVD, it would prevent an estimated 59 events
and save $761,000 per 1000 patients. CONCLUSION:
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Risk assessment and intervention programs that target
treated but uncontrolled hypertensives can be expected to
yield substantial economic benefits in addition to pre-
venting cardiovascular morbidity and mortality.
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ASSESSING THE BURDEN OF ILLNESS IN 
ELDERLY VERSUS YOUNGER ACUTE 
CORONARY SYNDROME PATIENTS
Eisenstein EL1, Peterson ED1, Shaw LK1, Hasselblad V1, 
Nelson CL1, Hakim Z2, Mark DB1
1Duke Clinical Research Institute, Durham, NC, USA; 2Roche 
Global Pharmacoeconomic Research, Palo Alto, CA, USA
OBJECTIVES: To compare the long-term clinical and
economic outcomes of elderly (75 years) versus younger
acute coronary syndrome patients. METHODS: We used
the Duke Cardiovascular Databank to identify patients
with a recent (6 weeks) myocardial infarction or unsta-
ble angina, index cardiac cath between 1986 and 1997,
significant coronary artery disease (CAD), and no previ-
ous cardiac procedures. Follow-up extended through
1998. We modeled clinical events (death, MI, coronary
artery bypass graft surgery (CABG), percutaneous coro-
nary intervention (PCI), and other rehospitalizations) to
12 years for pts with censored follow-up. We modeled in-
patient and outpatient medical costs for all patients using
inpatient costs from the GUSTO IIb clinical trial and
other secondary data sources. RESULTS: Elderly (n 
1401) vs. younger (n  8475) patients were more likely
female (58% vs. 32%) and non-smokers (41% vs. 69%),
had greater history of congestive heart failure (25% vs.
14%) and cerebral vascular disease (17% vs. 9%), less
single vessel disease (30% vs. 46%) and more three vessel
disease (43% vs. 26%), and greater 30-day mortality
(9.8% vs. 3.2%). While median 12-year medical costs
were greater for younger ($57,475) than for elderly
($53,431) patients, mean survival was less for elderly pa-
tients (6.4 vs. 9.3 years) yielding greater costs per year of
survival ($8075 vs. $6037) for the elderly. CONCLU-
SIONS: CAD patients undergoing an initial cardiac cath
after age 75 represent a high-risk group undetected by
current CAD screening algorithms. These findings point
to the need for improved screening tools and disease
management strategies in high-risk, pre-CAD popula-
tions.
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OBJECTIVES: Stroke is the third leading cause of death
and a leading cause of disability. We determined inci-
dence, and total direct costs of stroke by stroke type, age
group, gender and race. METHODS: We used an inci-
dence approach and aggregate national data sources to
determine 1998 US direct medical cost of stroke from a
societal perspective. We modeled the disease from first
hospitalization to end of first year. A sensitivity analysis
varied prevalence and utilization of each cost factor
around a base case. RESULTS: The incidence of first
stroke is 232/100,000 population of which 82% are is-
chemic strokes. The total annual costs of a first time
stroke are $25.2 billion. The first hospitalization ac-
counts for 20% of costs but all hospitalizations together
in the first year account for the highest proportion of
costs (65%, $15.9 billion). Those with subarachnoid
hemorrhagic stroke ($18,461) had first hospitalization
costs per stay more than three times higher than ischemic
stroke ($5,417) and more than two times higher than in-
tracerebral hemorrhagic stroke ($7,709). Also high are
costs for chronic disability care, which are $5.5 billion,
primarily home care ($3.9 billion). Sensitivity analysis
showed a maximum variation in cost from $15.8 to
$35.8 billion when varying incidence estimates. CON-
CLUSION: The societal cost burden is quite high and
caused primarily by disability factors. Although ischemic
stroke accounts for the highest total costs due to its
higher incidence, subarachnoid hemorrhagic stroke ac-
counts for more deaths and much higher first hospitaliza-
tion costs. This study demonstrates a high combined
acute and chronic care burden for stroke patients.
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OBJECTIVES: The importance of subsequent events on
health care costs following acute myocardial infarction
(AMI). METHODS: Patients with AMI (first admission 
index) were identified from Massachusetts (MA) 1996/
1997 patient-level discharge databases. Secondary events
(i.e., AMI, angina, CABG, PTCA, coronary angiography,
ischemic stroke, TIA, other related cardiovascular condi-
tions) occurring within 12 months were assessed in terms
of hospital costs, length of stay, discharge disposition
and post-acute care costs. These data were supplemented
by five additional state databases, fee schedules, other
agency and survey data, and the literature. All costs are
reported in 1998 US dollars adjusted for medical infla-
tion and cost-to-charge ratios. Log transformation was
used to address highly skewed distributions. RESULTS:
Of the 8,037 MA AMI patients, 86% were discharged
alive, and 54% of them were readmitted for another
event, 49% more than once. Of those readmitted, 8.9%
were hospitalized for a second AMI, 1.4% for a stroke. A
second AMI increases the use of post-discharge formal
health care services (e.g., skilled nursing facility, rehabili-
tation, home health care) by 19% and a stroke by 52%.
